VOLVO, PROCORDIA MERGER BARRED

3 February 1992

The Swedish government-owned food and drug manufacturer Procordia, and Sweden's car manufacturer, Volvo, reached an agreement allowing Volvo to become a majority shareholder in Procordia last week, but the Swedish government has rejected the proposed merger and was holding urgent talks with Volvo as the Marketletter went to press. Should the deal finally be allowed to go ahead, it would be Sweden's first privatization of a state-owned comp-any and one of Europe's biggest mergers.

The news of the agreement sent Procordia's shares plummeting, as the general feeling about the merger is that it would be good for Volvo, but not for Procordia. The latter's B-free shares dropped 6.6% in trading at the start of last week. Procordia, which controls Kabi Pharmacia, is offering nine of its shares for every four Volvo shares. Sweden's Prime Minister Carl Bildt said that the deal was "unacceptable" as it would mean too great a loss for the state.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight